Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

19(T2)28z1xx TRAC T cell

Phase 1 · mab · B-Cell Lymphoma

19(T2)28z1xx TRAC T cell for B-Cell Lymphoma is a Phase 1 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 1 mab active

Internal code 22-401

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 1
Modality
mab
Indication
B-Cell Lymphoma
Status
active
Trials
1